Atlas Venture Associates IX’s Surface Oncology, Inc. Common Stock SURF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,945,453
| Closed | -$2.56M | – | 7 |
|
|
2023
Q2 | $2.56M | Hold |
2,945,453
| – | – | 14.02% | 2 |
|
|
2023
Q1 | $2.06M | Hold |
2,945,453
| – | – | 9.68% | 2 |
|
|
2022
Q4 | $2.42M | Hold |
2,945,453
| – | – | 12.02% | 2 |
|
|
2022
Q3 | $3.06M | Hold |
2,945,453
| – | – | 9.08% | 2 |
|
|
2022
Q2 | $4.83M | Hold |
2,945,453
| – | – | 10.98% | 2 |
|
|
2022
Q1 | $8.66M | Hold |
2,945,453
| – | – | 7.96% | 3 |
|
|
2021
Q4 | $14.1M | Hold |
2,945,453
| – | – | 6.15% | 3 |
|
|
2021
Q3 | $22.3M | Hold |
2,945,453
| – | – | 7.41% | 3 |
|
|
2021
Q2 | $22M | Hold |
2,945,453
| – | – | 3.87% | 2 |
|
|
2021
Q1 | $23M | Hold |
2,945,453
| – | – | 3.86% | 3 |
|
|
2020
Q4 | $27.2M | Sell |
2,945,453
-1,700,000
| -37% | -$14.8M | 4.31% | 3 |
|
|
2020
Q3 | $32.1M | Hold |
4,645,453
| – | – | 33.16% | 2 |
|
|
2020
Q2 | $30.5M | Hold |
4,645,453
| – | – | 32.59% | 2 |
|
|
2020
Q1 | $8.69M | Hold |
4,645,453
| – | – | 18.37% | 3 |
|
|
2019
Q4 | $8.73M | Hold |
4,645,453
| – | – | 15.22% | 3 |
|
|
2019
Q3 | $6.6M | Hold |
4,645,453
| – | – | 10.86% | 3 |
|
|
2019
Q2 | $13.1M | Hold |
4,645,453
| – | – | 14.01% | 4 |
|
|
2019
Q1 | $22.2M | Hold |
4,645,453
| – | – | 20.82% | 2 |
|
|
2018
Q4 | $19.7M | Hold |
4,645,453
| – | – | 22.68% | 2 |
|
|
2018
Q3 | $50.8M | Hold |
4,645,453
| – | – | 26.9% | 1 |
|
|
2018
Q2 | $75.8M | Buy |
+4,645,453
| New | +$67.2M | 33.35% | 1 |
|
Atlas Venture Associates IX's SURF Position: Q3 2023 in Review
Atlas Venture Associates IX sold out of Surface Oncology, Inc. Common Stock (SURF) in Q3 2023, closing a stake of 2,945,453 shares — an estimated $2.56M sold.
Atlas Venture Associates IX first reported a position in SURF in Q2 2018 and held it in 21 quarters. The position peaked at $75.8M in Q2 2018. 0 funds tracked by Wall St. Rank hold SURF as of Q3 2023.
- Atlas Venture Associates IX reported no remaining Surface Oncology, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Atlas Venture Associates IX sold 2,945,453 Surface Oncology, Inc. Common Stock shares in Q3 2023, an estimated $2.56M.
- Atlas Venture Associates IX first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 21 quarters.
- Atlas Venture Associates IX's Surface Oncology, Inc. Common Stock position peaked at $75.8M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2023.
Based on Atlas Venture Associates IX's 13F filing for Q3 2023, filed 13 Nov 2023.